Core Viewpoint - Waystar Holding Corp. will report its financial results for Q3 2025 on October 29, 2025, after market close, followed by a conference call to discuss the results [1]. Company Overview - Waystar provides healthcare payment software designed to simplify payment processes, allowing providers to focus on patient care and financial performance [3]. - The company serves approximately 30,000 clients, which includes over 1 million distinct providers, and 17 out of the 20 institutions listed in U.S. News Best Hospitals [3]. - Waystar's platform processes over 6 billion healthcare payment transactions annually, managing over $1.8 trillion in gross claims and covering about 50% of U.S. patients [3].

TORONTO, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Vitalhub Corp. (TSX:VHI) (OTCQX:VHIBF) (the "Company" or "VitalHub") announced that Novari Health (“Novari”), a VitalHub company, has been commissioned for its first UK deployment with the South West Provider Collaborative for its electronic referral and bed management workflow solution. The deployment will expand Novari’s geographic footprint beyond current implementations in Canada and Australia. The South West Provider Collaborative is a National Health Service ...

Company Overview - Judi Health, founded by AJ Loiacono, aims to address inefficiencies in the healthcare industry, which incurs $1 trillion in administrative spending annually [1] - The company, previously known as Capital Rx, has developed a modular cloud-based software that enhances pricing transparency in pharmacy benefit management [4] Financial Performance - Judi Health has achieved a revenue expectation of $3.7 billion for the current year, reflecting a growth of over 75% from last year's revenue of $2.1 billion [5] - The company recently announced a $400 million investment, including a $252 million Series F funding round, which has doubled its valuation to $3.25 billion [2] Operational Efficiency - Judi Health has successfully reduced costs by 11% for 1,800 plan members and decreased claims processing times from over six months to 18 days [1] - The company's pricing model involves charging flat administrative fees based on a per-member monthly basis or per-claim structure, utilizing the national average drug acquisition cost database for drug pricing [4] Market Context - U.S. pharmacy spending is projected to increase by $50 billion in 2024, reaching $487 billion at net manufacturer prices, driven by growth in various therapeutic areas including oncology and diabetes [5]

Hinge Health Inc. (NYSE:HNGE) is one of the best new stocks to buy right now. On September 11, Stifel analyst David Grossman raised the firm’s price target on Hinge Health to $66 from $63, while keeping a Buy rating on the shares. The firm believes that there is significant momentum behind Hinge’s business. In Q2 2025, Hinge Health reported a 55% year-over-year increase in revenue, which reached $139 million. The company has significantly expanded its network and now has over 50 partners, which include th ...

Core Insights - Wayar is hosting its True North conference in Nashville to showcase new AI solutions in healthcare software, addressing the challenges of higher utilization and costs faced by healthcare providers [1][3] - The healthcare sector has seen a significant increase in patient visits, averaging 1-2% annually over the last 40 years, with a notable 4% increase in the last two years, necessitating more efficient resource management by hospitals [5] - Wayar's AI technology automates low complexity, high volume tasks, allowing healthcare providers to improve efficiency and accuracy in patient interactions and billing processes [5][7] Company Overview - Wayar processes over six billion insurance transactions annually, amounting to more than $1.8 trillion in gross claim charges, enabling better financial transparency for patients [9] - The company aims to transition from AI hype to a reality focused on return on investment (ROI) for healthcare providers, enhancing patient-provider interactions [8][12] - Wayar's software platform allows providers to help patients understand their financial responsibilities before receiving care, promoting a more consumer-friendly experience [10][11] Industry Context - The healthcare industry is experiencing a shift towards utilizing AI to manage increased patient interactions, including telehealth and virtual consultations, which are becoming integral to patient care [6] - There is a growing emphasis on price transparency in healthcare, with mandates for providers to publish prices for certain services, and Wayar is positioned to facilitate this process [11]

Joining me now in an exclusive interview is Wayar CEO Matt Hawkins. His company is hosting its True North conference in Nashville this week to spotlight potential new AI solutions in healthcare software. Matt, welcome.Setting the table here a bit. It's interesting to me uh United Health, for example, has been having so much trouble lately in in part because of higher utilization uh and costs. I guess that's transactions and that that hunger for transactions is part of why you've been doing well.>> Well, we' ...

Core Viewpoint - Waystar Holding Corp. has announced the pricing of an underwritten secondary offering of 18,000,000 shares of common stock at a public price of $39.40 per share, with the offering expected to close on or about September 12, 2025 [1][2]. Company Overview - Waystar is a provider of healthcare payments software, serving approximately 30,000 clients and over 1 million distinct providers, including 16 of the top 20 institutions on the U.S. News Best Hospitals list [5]. - The company's platform processes over 6 billion healthcare payment transactions annually, amounting to over $1.8 trillion in gross claims, covering approximately 50% of U.S. patients [5]. Offering Details - The offering is being conducted by certain investment funds of EQT AB, Bain Capital, LP, and Canada Pension Plan Investment Board, with Waystar not selling any shares or receiving proceeds from the sale [1]. - J.P. Morgan is acting as the underwriter for the offering [2]. - A registration statement on Form S-3 has been filed with the SEC and has become effective [3].

Group 1 - Pheresis, Inc. (NASDAQ:PHR) is recognized as one of the 14 Best Small Cap Stocks to Buy Right Now, with a price target raised from $35 to $36 by Truist Financial, maintaining a Buy rating [1] - The company's Q2 FY2026 results showed total revenue of $117.3 million, reflecting a 15% increase year-over-year, and adjusted EBITDA of approximately $22 million, which is a significant increase of $16 million compared to the previous year [2] - Pheresis updated its FY2026 adjusted EBITDA outlook to a range of $87 million to $92 million, and retained its revenue outlook at $472 million to $482 million [3] Group 2 - Pheresis has signed a definitive agreement to acquire Access One for $160 million, which is expected to enhance its addressable market by nearly $6 billion [3] - The company provides comprehensive software solutions aimed at improving the operational and financial performance of healthcare organizations, including SaaS-based integrated tools for managing patient access, registration, and payments [4]

Core Insights - Phreesia Inc. reported stronger-than-expected second-quarter earnings, with earnings of 1 cent per share compared to a forecasted loss of 6 cents, and revenue increased by 15% year-over-year to $117.26 million, surpassing estimates [1] - The company announced a $160 million cash acquisition of AccessOne Parent Holdings, expected to close in the latter half of fiscal 2026, which is projected to add approximately $35 million in annual revenue and $11 million in adjusted EBITDA [2] - Phreesia reaffirmed its fiscal 2026 sales guidance of $472 million to $482 million, slightly above consensus estimates, and updated its adjusted EBITDA outlook to $87 million to $92 million [3] Financial Performance - The average number of healthcare service clients increased by 7% to 4,467, with revenue per client also rising by 7% to $26,249 [1] - Adjusted EBITDA surged to $22.1 million from $6.5 million a year earlier [1] Analyst Reactions - Analysts expressed concerns about integration risks associated with the acquisition, despite acknowledging the solid second-quarter results [3] - Needham maintained a Buy rating on Phreesia and raised the price forecast from $29 to $35, while Piper Sandler reiterated an Overweight rating and increased the price forecast from $33 to $34 [4] Stock Performance - Phreesia's stock price fell by 8.35% to $28.61 during the last check on Friday [5]

Core Insights - HEALWELL AI Inc. reported a record revenue growth of 645% in Q2-2025, achieving quarterly revenue of $40.5 million compared to $5.4 million in Q2-2024, primarily driven by the acquisition of Orion Health [4][7][8] - The company achieved its first positive Adjusted EBITDA of $1.9 million in Q2-2025, a significant improvement from an Adjusted EBITDA loss of $3.7 million in Q2-2024, reflecting strong operational fundamentals [4][7][8] - HEALWELL's strategy is focused on becoming a pure-play software and services company, divesting its clinical research and patient services business units to enhance its AI and data science offerings [3][4][5] Financial Highlights - Revenue for Q2-2025 was $40.5 million, a 645% increase from $5.4 million in Q2-2024, with the Healthcare Software business experiencing a 1,064% year-over-year increase [4][7][13] - Gross Profit reached $21.3 million in Q2-2025, up 764% from $2.5 million in Q2-2024, resulting in a Gross Margin of 52.5%, compared to 45.2% in Q2-2024 [7][8][13] - The company had $19 million in cash as of June 30, 2025, an increase from $9.4 million at the end of 2024, positioning it well for future growth and acquisitions [5][7] Business and Operational Highlights - The acquisition of Orion Health, completed on April 1, 2025, is expected to contribute approximately $100 million in annual SaaS and services revenue, enhancing HEALWELL's global reach and customer base [4][7][8] - HEALWELL's AI segment achieved revenues of $5.1 million in the first half of 2025, representing a 223% year-over-year growth [8] - The company has identified several potential tuck-in M&A opportunities as part of its growth strategy [3][4] Strategic Initiatives - HEALWELL is focusing on integrating its AI solutions into public and private health systems, leveraging existing customer bases to accelerate adoption [3][4] - The company officially entered the U.S. healthcare market on June 11, 2025, launching AI-enabled tools targeting health systems and life sciences organizations [7][8] - The Board of Directors is exploring strategic alternatives for the clinical research and patient services business units to streamline operations and focus on high-margin software and services [4][5]